Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Sales to Working Capital Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -23.66%

Agios Pharm Sales to Working Capital Ratio 5 year CAGR is -23.66% for the Trailing 12 Months (TTM) ending March 31, 2024, a -5.47% change year over year. The sales to working capital ratio measures the revenue generated by a company relative to its working capital. It is calculated by dividing the revenue by the difference between current assets and current liabilities. This ratio indicates the company's revenue generation efficiency based on its working capital. A higher sales to working capital ratio suggests better utilization of working capital to generate sales revenue. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Agios Pharm Sales to Working Capital Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.01, a 4.53% change year over year.
Agios Pharm Sales to Working Capital Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.01, a -88.48% change year over year.
Agios Pharm Sales to Working Capital Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.05, a -43.17% change year over year.
Agios Pharm Sales to Working Capital Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.09, a 74.90% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends